These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 8678389)

  • 1. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.
    Graham BS; Keefer MC; McElrath MJ; Gorse GJ; Schwartz DH; Weinhold K; Matthews TJ; Esterlitz JR; Sinangil F; Fast PE
    Ann Intern Med; 1996 Aug; 125(4):270-9. PubMed ID: 8678389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
    AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
    Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
    JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.
    Gorse GJ; Patel GB; Newman FK; Belshe RB; Berman PW; Gregory TJ; Matthews TJ
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):378-86. PubMed ID: 8807200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
    Keefer MC; Graham BS; Belshe RB; Schwartz D; Corey L; Bolognesi DP; Stablein DM; Montefiori DC; McElrath MJ; Clements ML
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1713-23. PubMed ID: 7888231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.
    Gupta K; Hudgens M; Corey L; McElrath MJ; Weinhold K; Montefiori DC; Gorse GJ; Frey SE; Keefer MC; Evans TG; Dolin R; Schwartz DH; Harro C; Graham B; Spearman PW; Mulligan M; Goepfert P;
    J Acquir Immune Defic Syndr; 2002 Mar; 29(3):254-61. PubMed ID: 11873074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
    Belshe RB; Gorse GJ; Mulligan MJ; Evans TG; Keefer MC; Excler JL; Duliege AM; Tartaglia J; Cox WI; McNamara J; Hwang KL; Bradney A; Montefiori D; Weinhold KJ
    AIDS; 1998 Dec; 12(18):2407-15. PubMed ID: 9875578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
    Clements-Mann ML; Weinhold K; Matthews TJ; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Hsieh RH; Mestecky J; Zolla-Pazner S; Mascola J; Schwartz D; Siliciano R; Corey L; Wright PF; Belshe R; Dolin R; Jackson S; Xu S; Fast P; Walker MC; Stablein D; Excler JL; Tartaglia J; Paoletti E
    J Infect Dis; 1998 May; 177(5):1230-46. PubMed ID: 9593008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
    McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.
    Pialoux G; Excler JL; Rivière Y; Gonzalez-Canali G; Feuillie V; Coulaud P; Gluckman JC; Matthews TJ; Meignier B; Kieny MP
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):373-81. PubMed ID: 7598771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences.
    Nitayaphan S; Khamboonruang C; Sirisophana N; Morgan P; Chiu J; Duliege AM; Chuenchitra C; Supapongse T; Rungruengthanakit K; deSouza M; Mascola JR; Boggio K; Ratto-Kim S; Markowitz LE; Birx D; Suriyanon V; McNeil JG; Brown AE; Michael RA
    Vaccine; 2000 Feb; 18(15):1448-55. PubMed ID: 10618542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
    Salmon-Céron D; Excler JL; Sicard D; Blanche P; Finkielstzjen L; Gluckman JC; Autran B; Matthews TJ; Meignier B; Kieny MP
    AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1479-86. PubMed ID: 8679292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers.
    Kahn JO; Sinangil F; Baenziger J; Murcar N; Wynne D; Coleman RL; Steimer KS; Dekker CL; Chernoff D
    J Infect Dis; 1994 Nov; 170(5):1288-91. PubMed ID: 7963729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization.
    Migasena S; Suntharasamai P; Pitisuttithum P; Kitayaporn D; Wasi C; Huang W; Vanichseni S; Koompong C; Kaewkungwal J; Raktham S; Ippolito T; Hanson C; Gregory T; Heyward WL; Berman P; Francis D
    AIDS Res Hum Retroviruses; 2000 May; 16(7):655-63. PubMed ID: 10791876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.
    Cleghorn F; Pape JW; Schechter M; Bartholomew C; Sanchez J; Jack N; Metch BJ; Hansen M; Allen M; Cao H; Montefiori DC; Tomaras GD; Gurunathan S; Eastman DJ; do Lago RF; Jean S; Lama JR; Lawrence DN; Wright PF;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):222-30. PubMed ID: 17693888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine.
    Schwartz DH; Gorse G; Clements ML; Belshe R; Izu A; Duliege AM; Berman P; Twaddell T; Stablein D; Sposto R
    Lancet; 1993 Jul; 342(8863):69-73. PubMed ID: 8100910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.
    Gorse GJ; Patel GB; Mandava M; Berman PW; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jul; 15(10):921-30. PubMed ID: 10408729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.
    Dolin R; Graham BS; Greenberg SB; Tacket CO; Belshe RB; Midthun K; Clements ML; Gorse GJ; Horgan BW; Atmar RL
    Ann Intern Med; 1991 Jan; 114(2):119-27. PubMed ID: 1984386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.